Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-11-12 DOI:10.1080/14796694.2024.2421151

Bei Wang, Zixuan Wang, Kun Wang, Zhongming Shao, Haitao Chen, Lincheng Xu, Yan Pan, Mingyue Zheng, Wei Geng, Chuanhai Xu

{"title":"Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer.","authors":"Bei Wang, Zixuan Wang, Kun Wang, Zhongming Shao, Haitao Chen, Lincheng Xu, Yan Pan, Mingyue Zheng, Wei Geng, Chuanhai Xu","doi":"10.1080/14796694.2024.2421151","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the prognostic value of inflammatory markers in esophageal squamous cell carcinoma (ESCC) patients treated with immune checkpoint inhibitors (ICIs).Materials & methods: The infiltration of CD3+ and CD8+ T cells in tissue microarrays from 180 patients who underwent radical esophagectomy was detected using immunohistochemistry. A separate cohort of 351 patients with metastatic/recurrent or unresectable ESCC treated with ICIs was enrolled for further investigation. The overall survival difference among groups was assessed using Kaplan-Meier analysis. Cox proportional hazards models were employed to investigate the prognostic impact of the inflammatory markers, along with other factors.Results: Decreased inflammation was found to be associated with increased CD3+ and CD8+ T-cell infiltration and a better prognosis. Then, the value of inflammatory markers in predicting survival in 351 ESCC patients receiving immunotherapy was validated. Ultimately, the systemic immune-inflammation index was identified as an independent prognostic factor for overall survival. Additionally, the patients with no distant organ metastasis, or treated by first-line immunotherapy combined with concurrent chemoradiotherapy can considerably prolong survival.Conclusion: Inflammation is associated with the level of tumor infiltrating lymphocytes and that the systemic immune-inflammation index is an effective prognostic predictor for ESCC patients treated with ICIs.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2421151","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the prognostic value of inflammatory markers in esophageal squamous cell carcinoma (ESCC) patients treated with immune checkpoint inhibitors (ICIs).Materials & methods: The infiltration of CD3⁺ and CD8⁺ T cells in tissue microarrays from 180 patients who underwent radical esophagectomy was detected using immunohistochemistry. A separate cohort of 351 patients with metastatic/recurrent or unresectable ESCC treated with ICIs was enrolled for further investigation. The overall survival difference among groups was assessed using Kaplan-Meier analysis. Cox proportional hazards models were employed to investigate the prognostic impact of the inflammatory markers, along with other factors.Results: Decreased inflammation was found to be associated with increased CD3⁺ and CD8⁺ T-cell infiltration and a better prognosis. Then, the value of inflammatory markers in predicting survival in 351 ESCC patients receiving immunotherapy was validated. Ultimately, the systemic immune-inflammation index was identified as an independent prognostic factor for overall survival. Additionally, the patients with no distant organ metastasis, or treated by first-line immunotherapy combined with concurrent chemoradiotherapy can considerably prolong survival.Conclusion: Inflammation is associated with the level of tumor infiltrating lymphocytes and that the systemic immune-inflammation index is an effective prognostic predictor for ESCC patients treated with ICIs.

查看原文本刊更多论文

炎症标记物与淋巴细胞浸润相关，可预测食管癌免疫疗法的预后。

目的：研究接受免疫检查点抑制剂（ICIs）治疗的食管鳞状细胞癌（ESCC）患者炎症标志物的预后价值：采用免疫组化方法检测了180名接受根治性食管切除术的患者组织芯片中CD3+和CD8+T细胞的浸润情况。另外，还对 351 例接受 ICIs 治疗的转移性/复发性或不可切除 ESCC 患者进行了进一步研究。采用Kaplan-Meier分析法评估了各组间的总生存率差异。采用Cox比例危险模型研究炎症标志物和其他因素对预后的影响：结果：研究发现，炎症标志物的减少与 CD3+ 和 CD8+ T 细胞浸润的增加以及较好的预后相关。随后，对接受免疫疗法的351名ESCC患者的炎症标志物预测生存率的价值进行了验证。最终，全身免疫炎症指数被确定为总生存期的独立预后因素。此外，无远处器官转移或接受一线免疫治疗并同时接受化放疗的患者可大大延长生存期：结论：炎症与肿瘤浸润淋巴细胞水平有关，全身免疫炎症指数是预测接受 ICIs 治疗的 ESCC 患者预后的有效指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.